Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 8, 2022
Context: This filing incorporates by reference a press release regarding the expected timing of data readout for the company's Phase III Psoriasis study.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disseminate a corporate announcement and does not contain financial statements.
Material Changes
No material financial changes versus prior periods are reported in this filing. The primary update is operational, concerning the clinical development timeline.
Guidance, Outlook, and Management Commentary
- Clinical Outlook: Management expects data from the Phase III Psoriasis study to be available in the second quarter (Q2) of 2022.
- Management Commentary: The filing references a press release issued on March 8, 2022, titled "Can-Fite's Phase III Psoriasis Study Data Expected Q2 2022."
- Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K.
Key Facts for Investor Verification
- Verify the specific date of the Q2 2022 data readout for the Phase III Psoriasis study in the attached press release (Exhibit 99.1).
- Confirm the current cash runway and burn rate in the most recent quarterly or annual report, as this filing contains no financial data.
- Monitor subsequent filings for the actual release of Phase III study results.